Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

HOUSTON--(BUSINESS WIRE)--ImmunoMet Therapeutics ... in patients with advanced pancreatic cancer (NCT05497778). The study is led by Shubham Pant, MD, Professor of Gastrointestinal Medical Oncology ...

The study found that Prequel ® Prenatal Screen with AMPLIFY™ technology enables reliable results as early as eight-weeks’ gestation. Typically, prenatal cell-free DNA (pcfDNA) screening is offered ...

Blueprint Medicines Corporation ( NASDAQ: BPMC) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET ...

All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...

Fukuda-san is perfectly bald, with a luxuriant mustache. His work has been described as “kind of British,” which means he ...

Berlín, a city of 20,000 people, is home to El Salvador’s second Bitcoin circular economy. “Bitcoin City already exists. It’s ...

Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95 patients enrolled ...

The department tracks student achievement, manages college financial aid and sends K-12 schools money to support students ...

The home of media agent Jay Sures was vandalized by a group of anti-Israel protesters on Wednesday, who plastered his garage ...